Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $104.97, for a total value of $1,049,700.00. Following the completion of the transaction, the senior vice president owned 14,219 shares in the company, valued at $1,492,568.43. This represents a 41.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arjun Agarwal also recently made the following trade(s):
- On Monday, October 12th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.60, for a total value of $805,919.40.
- On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.75, for a total transaction of $51,034.75.
- On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60.
- On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total transaction of $872,403.57.
Oruka Therapeutics Stock Performance
Oruka Therapeutics stock traded up $0.36 during mid-day trading on Friday, hitting $105.35. 679,678 shares of the company traded hands, compared to its average volume of 1,033,539. Oruka Therapeutics, Inc. has a one year low of $25.23 and a one year high of $115.51. The stock has a market cap of $7.14 billion, a price-to-earnings ratio of -49.93 and a beta of -0.34. The stock has a fifty day moving average price of $89.68 and a 200-day moving average price of $72.36.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). Sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.52 EPS for the current year.
Wall Street Analysts Forecast Growth
ORKA has been the topic of a number of research reports. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Guggenheim reissued a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a research note on Monday, October 26th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $141.80.
Get Our Latest Analysis on ORKA
Institutional Investors Weigh In On Oruka Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Nykredit A S bought a new position in Oruka Therapeutics during the 2nd quarter worth approximately $29,000. GAMMA Investing LLC lifted its position in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after purchasing an additional 250 shares during the last quarter. Orion Capital Management LLC bought a new stake in Oruka Therapeutics in the second quarter valued at approximately $91,000. Sterling Capital Management LLC boosted its stake in shares of Oruka Therapeutics by 839.0% during the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock valued at $138,000 after purchasing an additional 1,485 shares during the period. Finally, Natural Investments LLC purchased a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $202,000. Institutional investors own 56.44% of the company’s stock.
More Oruka Therapeutics News
Here’s some of the latest news about ORKA:
- Positive Sentiment: BTIG Research and UBS each assigned Oruka a “Buy” rating, providing a positive analyst view. BTIG Research Buy rating UBS Buy rating
- Negative Sentiment: HC Wainwright cut its estimates for every quarter of 2027 and for full-year 2026 and 2027, while keeping its Buy rating. It now expects losses of $2.69 per share in FY2026 and $3.22 in FY2027, versus prior estimates of $2.54 and $2.82, respectively. The deeper projected losses may dampen sentiment.
- Negative Sentiment: Director Kristine M. Ball sold 18,000 shares—half her position—and SVP Arjun Agarwal sold 10,000 shares, reducing his holdings by 41.29%. Both sales were made under pre-arranged Rule 10b5-1 plans, which may lessen their significance as a signal about near-term prospects. Director Form 4 filing SVP Form 4 filing
About Oruka Therapeutics
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Recommended Stories
- Five stocks we like better than Oruka Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
